CADTH Canadian Drug Expert Committee recommendation. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features.

CADTH Canadian Drug Expert Committee recommendation. indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) :

Show other versions (6)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.

Saved in:
Bibliographic Details
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, November 21, 2017.
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Multiple Sclerosis, Relapsing-Remitting > drug therapy.
Antibodies, Monoclonal, Humanized > therapeutic use.
Immunologic Factors > therapeutic use.
Antibodies, Monoclonal, Humanized > economics.
Cost-Benefit Analysis.
Insurance, Health, Reimbursement.
Canada.
Online Access:http://www.ncbi.nlm.nih.gov/books/NBK535510/
Full text
http://www.ncbi.nlm.nih.gov/books/NBK533397/
Full text
http://www.ncbi.nlm.nih.gov/books/NBK534395/
Full text
http://www.ncbi.nlm.nih.gov/books/NBK535510/
Full text
http://www.ncbi.nlm.nih.gov/books/NBK533397/
Full text
http://www.ncbi.nlm.nih.gov/books/NBK534395/
Full text

MCPHS

Holdings details from MCPHS
Call Number: NCBI

Similar Items